Literature DB >> 10556129

The spectrum of mycobacterial infection after lung transplantation.

M A Malouf1, A R Glanville.   

Abstract

Despite the success of lung transplantation, infection is one of the leading causes of morbidity and mortality. Mycobacterial infections have been reported rarely, with the majority due to Mycobacterium tuberculosis. Our aim was to assess the incidence, etiology, and clinical outcome of mycobacterial infection after lung transplantation; to do so, we have studied retrospectively all lung and heart- lung transplants performed over a 12-yr period between November 1986 and June 1998 (n = 261). Twenty-three patients (9%) (M:F, 11:12) were diagnosed with mycobacterial infections in 25 sites, including n = 19, pulmonary (M. avium complex [n = 13], M. tuberculosis [n = 2], M. abscessus [n = 2], M. asiaticum [n = 1], and M. kansasii [n = 1]) and n = 6 extrapulmonary (M. haemophilum [n = 5] and M. abscessus [n = 1]) infections. Time to diagnosis from transplantation was 677 +/- 735 d (range, 2- 3,086 d). Three episodes of transient colonization with M. avium were not treated; the remaining (22 of 25, 88%) were treated. Initial baseline therapy for nontuberculous mycobacteria included clarithromycin, rifampicin, ciprofloxacin, and/or ethambutol. All cutaneous lesions resolved completely, while clinical and graft function improved in 11 of 16 (69%) and 8 of 16 (50%) of patients treated, respectively. Seventeen of 23 patients (72%) survived at a follow-up of 1,658 +/- 759 d (range, 522-3,285 d). Complications, predominantly due to rifampicin, included gastrointestinal intolerance and an increased tendency for rejection. There were no deaths attributable to mycobacterial disease or therapy. We conclude that mycobacterial infection, particularly due to nontuberculous mycobacteria, is relatively common after lung transplantation and may be an unrecognized cause of graft dysfunction. Early treatment of cutaneous lesions is associated with excellent control; however, graft dysfunction may be permanent. Although drug toxicity and interactions with immunosuppressive agents were not infrequent, the majority of these infections can be managed successfully.

Entities:  

Mesh:

Year:  1999        PMID: 10556129     DOI: 10.1164/ajrccm.160.5.9808113

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  29 in total

Review 1.  Nontuberculous mycobacteria and the lung: from suspicion to treatment.

Authors:  Emmet E McGrath; Zoe Blades; Josie McCabe; Hannah Jarry; Paul B Anderson
Journal:  Lung       Date:  2010-04-09       Impact factor: 2.584

2.  First report of disseminated Mycobacterium skin infections in two liver transplant recipients and rapid diagnosis by hsp65 gene sequencing.

Authors:  Susanna K P Lau; Shirly O T Curreem; Antonio H Y Ngan; Chi-Keung Yeung; Kwok-Yung Yuen; Patrick C Y Woo
Journal:  J Clin Microbiol       Date:  2011-08-31       Impact factor: 5.948

Review 3.  Lung transplantation: infection, inflammation, and the microbiome.

Authors:  Takeshi Nakajima; Vyachesav Palchevsky; David L Perkins; John A Belperio; Patricia W Finn
Journal:  Semin Immunopathol       Date:  2011-01-27       Impact factor: 9.623

Review 4.  Nontuberculous mycobacteria infection in solid organ transplant recipients.

Authors:  C Piersimoni
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-07-07       Impact factor: 3.267

Review 5.  Lung transplantation for cystic fibrosis: results, indications, complications, and controversies.

Authors:  Joseph P Lynch; David M Sayah; John A Belperio; S Sam Weigt
Journal:  Semin Respir Crit Care Med       Date:  2015-03-31       Impact factor: 3.119

6.  Non-tuberculous mycobacterium infection after lung transplantation is associated with increased mortality.

Authors:  Hsuanwen C Huang; S Samuel Weigt; Ariss Derhovanessian; Vyacheslav Palchevskiy; Abbas Ardehali; Rajan Saggar; Rajeev Saggar; Bernard Kubak; Aric Gregson; David J Ross; Joseph P Lynch; Robert Elashoff; John A Belperio
Journal:  J Heart Lung Transplant       Date:  2011-04-08       Impact factor: 10.247

7.  Molecular epidemiology of Mycobacterium abscessus, with focus on cystic fibrosis.

Authors:  Bodil E Jönsson; Marita Gilljam; Anders Lindblad; Malin Ridell; Agnes E Wold; Christina Welinder-Olsson
Journal:  J Clin Microbiol       Date:  2007-03-21       Impact factor: 5.948

8.  Update on nontuberculous mycobacterial infections in solid organ and hematopoietic stem cell transplant recipients.

Authors:  B M Knoll
Journal:  Curr Infect Dis Rep       Date:  2014-09       Impact factor: 3.725

9.  Non-tuberculous mycobacteria in end stage cystic fibrosis: implications for lung transplantation.

Authors:  W Chalermskulrat; N Sood; I P Neuringer; T M Hecker; L Chang; M P Rivera; L J Paradowski; R M Aris
Journal:  Thorax       Date:  2006-04-06       Impact factor: 9.139

Review 10.  Non-tuberculous Mycobacterial Infections in Thoracic Transplant Candidates and Recipients.

Authors:  Mana Rao; Fernanda P Silveira
Journal:  Curr Infect Dis Rep       Date:  2018-05-12       Impact factor: 3.725

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.